Ilene Fischer, MD
Gynecology · New York, NYNPI 1669420857
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Myriad Women's Health, Inc. at 52.9% of the total. Reporting peaked in 2023 at $3,360 and has fallen 94.8% since, to $176 in 2024.
Across 44 payments — averaging $136.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Women's Health, Inc.$3K
- Gynesonics, Inc.$2K
- Pfizer$246
- Astellas Pharma US Inc$154
- AbbVie$145
- Myovant Sciences Inc.$93
- plus $354 from 11 others
What the payments were for
- Speaking & faculty fees$2,80047%
- Travel & lodging$1,44524%
- Food & beverage$1,77129%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Women's Health, Inc. | 5 | $3,181 |
| Gynesonics, Inc. | 6 | $1,842 |
| Pfizer | 8 | $246 |
| Astellas Pharma US Inc | 2 | $154 |
| AbbVie | 2 | $145 |
| Myovant Sciences Inc. | 4 | $93 |
| Merck | 4 | $68 |
| Therapeuticsmd, Inc. | 2 | $47 |
| Coopersurgical, Inc. | 2 | $45 |
| Evofem Biosciences, Inc. | 2 | $37 |
| Davol Inc. | 1 | $35 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Medtronic | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Agile Therapeutics, Inc. | 1 | $20 |
| Organon | 1 | $19 |
| Lupin Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$3,181
- Sonata System$1,486
- Sontata System$275
- Orilissa$125
- Veozah$125
- MYFEMBREE$102
How this compares
$6,016 in reported general payments places this provider in the 85th percentile of 240 gynecology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 65 | $9,036 |
| Clobetasol Propionate | 15 | $1,497 |
Paid to pharmacies, not to this prescriber.
Other gynecology in New York
- Arnold AdvinculaNew York$2.1M
- Tamara KolevNew York$91K
- Charles Ascher-WalshNew York$43K
- Paula CastanoNew York$31K
- Christopher EswarNew York$25K
- Neena AgarwalaNew York$17K
- Tara AllmenNew York$8K
- Jorge VenegasNew York$7K
- Molly McBrideNew York$7K
- Connie LiuNew York$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.